Cytokinetics, Incorporated (CYTK)

Cytokinetics Statistics

Total Valuation

Cytokinetics has a market cap or net worth of $5.77 billion. The enterprise value is $5.66 billion.

Market Cap	5.77B
Enterprise Value	5.66B

Important Dates

The last earnings date was Wednesday, November 6, 2024, after market close.

Earnings Date	Nov 6, 2024
Ex-Dividend Date	n/a

Share Statistics

Cytokinetics has 118.01 million shares outstanding. The number of shares has increased by 12.36% in one year.

Current Share Class	118.01M
Shares Outstanding	118.01M
Shares Change (YoY)	+12.36%
Shares Change (QoQ)	+7.73%
Owned by Insiders (%)	0.49%
Owned by Institutions (%)	116.64%
Float	117.39M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	726.64
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1,759.52
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.28

Current Ratio	9.28
Quick Ratio	9.22
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-6.48

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-30.13%
Return on Capital (ROIC)	-54.45%
Revenue Per Employee	$7,610
Profits Per Employee	-$1.36M
Employee Count	423
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +32.66% in the last 52 weeks. The beta is 0.79, so Cytokinetics's price volatility has been lower than the market average.

Beta (5Y)	0.79
52-Week Price Change	+32.66%
50-Day Moving Average	52.03
200-Day Moving Average	57.04
Relative Strength Index (RSI)	44.62
Average Volume (20 Days)	1,216,339

Short Selling Information

The latest short interest is 14.03 million, so 11.89% of the outstanding shares have been sold short.

Short Interest	14.03M
Short Previous Month	14.59M
Short % of Shares Out	11.89%
Short % of Float	11.95%
Short Ratio (days to cover)	10.52

Income Statement

In the last 12 months, Cytokinetics had revenue of $3.22 million and -$576.40 million in losses. Loss per share was -$5.38.

Revenue	3.22M
Gross Profit	-327.54M
Operating Income	-524.63M
Pretax Income	-545.28M
Net Income	-576.40M
EBITDA	-511.14M
EBIT	-524.63M
Loss Per Share	-$5.38

Balance Sheet

The company has $1.01 billion in cash and $908.23 million in debt, giving a net cash position of $103.47 million or $0.88 per share.

Cash & Cash Equivalents	1.01B
Total Debt	908.23M
Net Cash	103.47M
Net Cash Per Share	$0.88
Equity (Book Value)	-13.91M
Book Value Per Share	-0.12
Working Capital	908.79M

Cash Flow

In the last 12 months, operating cash flow was -$404.36 million and capital expenditures -$2.69 million, giving a free cash flow of -$407.05 million.

Operating Cash Flow	-404.36M
Capital Expenditures	-2.69M
Free Cash Flow	-407.05M
FCF Per Share	-$3.45

Margins

Gross Margin	n/a
Operating Margin	-16,297.79%
Pretax Margin	-17,906.24%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Cytokinetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.36%
Shareholder Yield	-12.36%
Earnings Yield	-9.99%
FCF Yield	-7.06%

Analyst Forecast

The average price target for Cytokinetics is $84.07, which is 72.03% higher than the current price. The consensus rating is "Buy".

Price Target	$84.07
Price Target Difference	72.03%
Analyst Consensus	Buy
Analyst Count	16
Revenue Growth Forecast (5Y)	155.20%
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on June 25, 2013. It was a reverse split with a ratio of 0.1666666:1.

Last Split Date	Jun 25, 2013
Split Type	Reverse
Split Ratio	0.1666666:1

Scores

Cytokinetics has an Altman Z-Score of -0.42 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.42
Piotroski F-Score	2